Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational study
- 131 Downloads
Acute kidney injury (AKI) remains a frequent complication after cardiac interventions, such as left atrial appendage closure (LAAC), yet limited data are available on the incidence and clinical implication of AKI in this setting. We sought to assess incidence, predictors and relevance of AKI after LAAC.
Methods and results
We retrospectively analyzed 95 LAAC patients in three European centers. AKI was defined according to the Acute Kidney Injury Network (AKIN) classification. The incidence of AKI was 13.7% with mild AKI in 92.3% and AKI stage > II in 7.7%. Total contrast volume was not linked to the occurrence of AKI (AKI: 127 ± 83 vs. no AKI: 109 ± 92 ml, p = 0.41), however increasing contrast volume (CV) to glomerular filtration rate (GFR) ratio (CV/GFR ratio) was associated with an increased risk of AKI (OR, per unit increase: 1.24, 95% CI 0.97–1.58, p = 0.08). ROC-analysis revealed a moderate predictive value of CV/GFR ratio for the prediction of AKI (AUC: 0.67, 95% CI 0.50–0.84, p = 0.05). Furthermore, AKI was associated with significantly increased mortality 6 months and 1 year after LAAC. No significant difference in the incidence of AKI was observed between patients with mere fluoroscopic and additional echocardiographic guidance (16.3% vs. 11.5%, p = 0.56).
Whereas mild AKI is common in patients after LAAC, severe AKI is rare. AKI after LAAC is associated with poor baseline renal function, increased doses of contrast (CV/GFR ratio) and impaired outcome. Future studies will be needed to elaborate the benefit of reducing or avoiding contrast volume regarding this endpoint.
KeywordsLeft atrial appendage closure Renal function Acute kidney injury Contrast dye volume
Amplatzer Cardiac Plug
Acute kidney injury
Acute Kidney Injury Network
Area under the curve
- CV/GFR ratio
Contrast volume to glomerular filtration rate ratio
Chronic kidney disease
Glomerular filtration rate
Kidney disease improving global outcomes
Left atrial appendage closure
Left ventricular ejection fraction
Percutaneous coronary intervention
Receiver operating characteristic
Transcatheter aortic valve replacement
All co-authors contributed fully in terms of the design of the study, the evaluation of data, the actual manuscript preparation, and the revision and approval of the final submitted manuscript. As the corresponding author, Dr. Gloekler confirms that all authors have approved the final text.
Compliance with ethical standards
Conflict of interest
Alexander Sedaghat has received travel grants from Abbott, Boston Scientific, Medtronic and Edwards Lifesciences. Baravan Al-Kassou has received travel grants from Abbott. Jan Wilko Schrickel has participated in clinical trials conducted by Abbott. Fabian Nietlispach is a consultant to Abbott, Edwards Lifesciences, and Medtronic. Marco Valgimigli reports research grants, advisory board and lectures fees from Abbott; Stephan Windecker received grants to the institution from Abbott, Biotronik, Boston Scientific, Medtronic and Edwards Lifesciences; Bernhard Meier received speaker and proctor fees from Abbott. Georg Nickenig has received speaker honoraria from Abbott. Steffen Gloekler received institutional grants from Abbott and a grant from the Swiss Heart Foundation. The other authors have no conflicts of interest.
Declaration of Helsinki: The authors state that the study complies with the Declaration of Helsinki. The locally appointed ethics committee has approved the research protocol. Informed consent has been obtained from the subjects.
- 1.Reddy VY, Holmes D, Doshi SK et al (2011) Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation 123:417–424. https://doi.org/10.1161/CIRCULATIONAHA.110.976449 CrossRefGoogle Scholar
- 3.Holmes DR, Kar S, Price MJ et al (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64:1–12. https://doi.org/10.1016/j.jacc.2014.04.029 CrossRefGoogle Scholar
- 5.Seeger J, Bothner C, Dahme T et al (2016) Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. Clin Res Cardiol 105:225–229. https://doi.org/10.1007/s00392-015-0910-8 CrossRefGoogle Scholar
- 18.Rihal CS, Textor SC, Grill DE et al (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264. https://doi.org/10.1161/01.CIR.0000016043.87291.33 CrossRefGoogle Scholar
- 22.Tsai TT, Patel UD, Chang TI et al (2014) Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR cath-PCI registry. JACC Cardiovasc Interv 7:1–9. https://doi.org/10.1016/j.jcin.2013.06.016 CrossRefGoogle Scholar
- 27.Laskey WK, Jenkins C, Selzer F et al (2007) Volume-to-creatinine clearance ratio. A pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 50:584–590. https://doi.org/10.1016/j.jacc.2007.03.058 CrossRefGoogle Scholar
- 30.Sedaghat A, Al-Kassou B, Vij V et al (2019) Contrast-free, echocardiography-guided left atrial appendage occlusion (LAAo): a propensity-matched comparison with conventional LAAo using the AMPLATZER™ Amulet™ device. Clin Res Cardiol 108:333–340. https://doi.org/10.1007/s00392-018-1401-5 CrossRefGoogle Scholar